Alaya.bio, an in vivo gene delivery biotech company, announces the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.
Alaya.bio, an in vivo gene delivery biotech company, announces the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.